Gemini Therapeutics, Inc. (GMTX) News
Filter GMTX News Items
GMTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest GMTX News From Around the Web
Below are the latest news stories about GEMINI THERAPEUTICS INC that investors may wish to consider to help them evaluate GMTX as an investment opportunity.
7 Short-Squeeze Stocks for Bold Contrarians to ConsiderWhile market volatility has brough the bears out of hibernation, certain short-squeeze stocks could be a trap for the pessimists. |
Disc Medicine Initiates AURORA, a Phase 2 Clinical Study of Bitopertin in Adults with Erythropoietic Protoporphyria (EPP)Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today the initiation of AURORA, a Phase 2 clinical study of bitopertin in adults with EPP. Bitopertin is an oral, selective inhibitor of glycine transporter 1 (GlyT1) designed to modulate heme biosynthesis, and has been shown in preclinical studies to reduce accumulation of protoporphyrin IX ( |
Gemini Therapeutics and Disc Medicine Announce Merger AgreementWAYLAND, Mass. & WATERTOWN, Mass., August 10, 2022--Gemini Therapeutics, Inc. (Nasdaq: GMTX) ("Gemini") and Disc Medicine, Inc. ("Disc"), a privately-held, clinical-stage biopharmaceutical company focused on the discovery and development of novel treatments for patients suffering from serious hematologic diseases, announced today that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Disc’s pipe |
Insider Buying: Braden Leonard Just Spent US$75k On Gemini Therapeutics, Inc. (NASDAQ:GMTX) SharesEven if it's not a huge purchase, we think it was good to see that Braden Leonard, a Gemini Therapeutics, Inc... |
Gemini Therapeutics Reports 2021 Financial ResultsRemote-First-Company/Mass., March 10, 2022--Gemini Therapeutics, Inc. (Nasdaq: GMTX) today reported financial results for the year ended December 31, 2021. |
Gemini Therapeutics Provides Corporate UpdateRemote-First-Company/Mass., February 28, 2022--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today provided a corporate update announcing a leadership transition, strategic evaluation and corporate restructuring. |
Gemini Therapeutics Provides GEM103 Program UpdateCAMBRIDGE, Mass., January 10, 2022--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced updates from its ongoing phase 2a clinical studies of GEM103 and strategic evaluation of GEM103’s clinical development program. |